RELMADA THERAPEUTICS, INC. Increase (Decrease) in Leasing Receivables
RELMADA THERAPEUTICS, INC. (RLMD) reported Increase (Decrease) in Leasing Receivables of -$86.38 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLeasingReceivables · last filed 2024-03-19
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for the quarter ending 2022-12-31 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for the quarter ending 2022-09-30 was -$42.23K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for the quarter ending 2022-06-30 was -$23.22K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for the quarter ending 2022-03-31 was -$20.92K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for fiscal 2022 was -$86.38K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for fiscal 2021 was -$79.46K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for fiscal 2020 was -$73.09K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in leasing receivables for fiscal 2019 was -$67.23K.
| Period end | Increase (Decrease) in Leasing Receivables 3 month | Increase (Decrease) in Leasing Receivables 6 month | Increase (Decrease) in Leasing Receivables 9 month | Increase (Decrease) in Leasing Receivables 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$42.23K derived: sum of 2 quarters · filed 2024-03-19 | -$65.45K derived: sum of 3 quarters · filed 2024-03-19 | -$86.38K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$42.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$65.45K derived: sum of 2 quarters · filed 2023-11-08 | -$86.38K 10-Q · filed 2023-11-08 | -$106.87K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$23.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$44.14K 10-Q · filed 2023-08-08 | -$64.63K derived: sum of 3 quarters · filed 2023-08-08 | -$84.70K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$20.92K 10-Q · filed 2023-05-11 | -$41.41K derived: sum of 2 quarters · filed 2023-05-11 | -$61.48K derived: sum of 3 quarters · filed 2023-05-11 | -$81.13K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$20.49K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$40.56K derived: sum of 2 quarters · filed 2023-03-23 | -$60.21K derived: sum of 3 quarters · filed 2023-03-23 | -$79.46K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$20.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$39.72K derived: sum of 2 quarters · filed 2022-11-10 | -$58.97K 10-Q · filed 2022-11-10 | -$77.82K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$19.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$38.90K 10-Q · filed 2022-08-11 | -$57.75K derived: sum of 3 quarters · filed 2022-08-11 | -$76.21K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$19.25K 10-Q · filed 2022-05-05 | -$38.10K derived: sum of 2 quarters · filed 2022-05-05 | -$56.56K derived: sum of 3 quarters · filed 2022-05-05 | -$74.63K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$18.85K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$37.31K derived: sum of 2 quarters · filed 2022-03-25 | -$55.39K derived: sum of 3 quarters · filed 2022-03-25 | -$73.09K 10-K · filed 2022-03-25 |
| 2020-09-30 | -$18.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$36.54K derived: sum of 2 quarters · filed 2021-11-12 | -$54.24K 10-Q · filed 2021-11-12 | -$71.58K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$18.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$35.78K 10-Q · filed 2021-08-10 | -$53.12K derived: sum of 3 quarters · filed 2021-08-10 | -$70.10K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$17.70K 10-Q · filed 2021-05-12 | -$35.04K derived: sum of 2 quarters · filed 2021-05-12 | -$52.02K derived: sum of 3 quarters · filed 2021-05-12 | -$68.65K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$17.34K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | -$34.32K 10-K · filed 2021-03-24 | -$50.95K derived: sum of 3 quarters · filed 2021-03-24 | -$67.23K 10-K · filed 2021-03-24 |
| 2019-09-30 | -$16.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$33.61K derived: sum of 2 quarters · filed 2020-11-12 | -$49.90K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$16.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$32.92K 10-Q · filed 2020-08-12 | -$64.49K 10-K · filed 2021-03-24 | |
| 2019-03-31 | -$16.29K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | -$31.57K 10-KT · filed 2020-03-26 | |||
| 2018-06-30 | -$59.32K 10-KT · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |